In AI-enabled drug discovery, there might be more than one winner


Share post:

elcome to the TechCrunch Exchange, a weekly startups-and-markets newsletter. It’s inspired by the daily TechCrunch+ column where it gets its name. Want it in your inbox every Saturday? Sign up here.

Today, a look at Israel from three different angles: drug discovery, AI-enabled cybersecurity threats, and investor reactions to the political crisis. — Anna

From spatial biology to proteomics

Chipmaker Nvidia invested $50 million into biotech startup Recursion, which now plans to “accelerate [the] development of its AI foundation models for biology and chemistry,” according to a press release.

Recursion CTO Ben Mabey said the company aims to build “a definitive foundation model for the drug discovery space.” That’s no easy feat; its CEO Chris Gibson referred to drug discovery as “one of the world’s most difficult challenges.”

However, both Recursion and Nvidia hope AI can help solve this challenge. “Generative AI is a revolutionary tool to discover new medicines and treatments,” Nvidia CEO Jensen Huang wrote in a canned statement.

Recursion is far from the only company working on this; in May, it acquired two companies in the AI-enabled drug discovery space, Cyclica and Valence. But while these three companies are headquartered in North America, I couldn’t help but notice that a number of their competitors are based in Israel.

I asked Lior Handelsman and Renana Ashkenazi, two general partners at Israeli VC firm Grove Ventures, why Israel may be an AI-enabled biotech hotbed. They mentioned some factors I was expecting, such as academic talent and the entrepreneurial spirit that already turned the country into a Startup Nation. But Ashkenazi also noted that the profile of biotech founders is changing.

Source link

Lisa Holden
Lisa Holden
Lisa Holden is a news writer for LinkDaddy News. She writes health, sport, tech, and more. Some of her favorite topics include the latest trends in fitness and wellness, the best ways to use technology to improve your life, and the latest developments in medical research.

Recent posts

Related articles

Pitch Deck Teardown: Transcend’s $20M Series B deck

If you’ve ever had to plan a large infrastructure project — like building a new section of...

Pixel Pals delivers a cute and clever update that takes advantage of new iOS features

Developer Christian Selig has launched an updated version of his playful Pixel Pals app that takes clever...

Power amplifier startup Falcomm to close $4M, taking on Qualcomm and Broadcom

Smartphones are equipped with a range of chips that perform various functions. Among them, there’s a semiconductor...

Microsoft’s mobile keyboard app SwiftKey gains new AI-powered features

Along with AI advances in Windows 11 and Bing, Microsoft also this week announced it’s bringing new...

Chris Lehane: The SEC isn’t handling crypto regulation ‘strategically’

As the regulatory landscape continues to be shaky for crypto players, some regulators may be overreaching when...

Intel (re)fined $400M by EU for ‘naked restrictions’ dating back to the noughties

Talk about old news: The European Union has reimposed a fine (totalling €376.36 million) on Intel for...

Amazon Prime Video will start showing ads from early next year

After Netflix and Disney+ introduced ad-supported plans last year, Amazon said in an update today that it will...

Threads adds easy profile switching to its mobile apps

Meta-owned Twitter rival Threads has finally added a way to switch between multiple accounts without logging out. The...